Chintan Dave, PharmD, PhD

Associate Professor of Pharmacy and Epidemiology,
Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health

Academic Director, Rutgers Center for Health Outcomes, Policy, and Economics (HOPE)

Chintan Dave, a pharmacoepidemiologist and health service researcher, joined PETS and Ernest Mario College of Pharmacy in 2019 as an Assistant Professor of Pharmacy. He received his pharmacy degree from St. Louis College of Pharmacy (2012), his Ph.D. in Pharmacoepidemiology from University of Florida (2017) and post-doctoral training from Harvard Medical School (2019). He has conducted several observational studies on the comparative safety and effectiveness of pharmaceuticals. His recent work has focused on the safety and cardiovascular effectiveness of Sodium-glucose co-transporter-2 inhibitors, a newer class of agents used for the management of diabetes. Broadly, his work leverages large observational databases and applies advanced statistical and epidemiological methods for confounding adjustment, within the areas of cardiometabolic and geriatric pharmacoepidemiology. He has led projects that have culminated in first author publications in leading journals like the New England Journal of Medicine, Annals of Internal Medicine and JAMA: Internal Medicine. He is the Assistant Director for industry fellowships at PETS, and the Academic Director at the Rutgers Center for Health Outcomes, Policy, and Economics (HOPE). Currently, he serves as the PI of an R01 award from NHLBI and a research award from JDRF.

Select Publications

1. Dave CV, Brittenham GM, Carson JL, Setoguchi S. Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study. Ann Intern Med. 2022 May;175(5):656-664. doi: 10.7326/M21-4009. 2022 PMID: 35344378.
2. Dave CV, Schneeweiss S, Patorno E, SGLT2 inhibitors and risk of Fournier’s Gangrene in men. JAMA Intern Med. 2019; (11):1587–1590. PMCID: PMC6724526
3. Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E, Sodium-glucose cotransporter 2 inhibitors and the risk of severe urinary tract infection events. Ann Intern Med. 2019;171 (4), 248-256
4. Dave CV, Hartzema A, Kesselheim AS. Prices of generic drugs associated with numbers of manufacturers. N Eng J Med. 377.26 (2017): 2597-2598.
5. Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High generic drug prices and market competition: a retrospective cohort study. Ann Intern Med. 167.3 (2017): 145-151.